How to Interpret a logP Value (and the Estimator Trap)

Two property panels, same molecule, two different logP values a full log unit apart. It happens more than chemists expect, and it isn’t a bug — it’s the consequence of reading a logP without knowing which estimator produced it. Knowing how to interpret a logP value for a drug means reading both the number and its method. This post covers what logP measures, the ranges that matter for oral compounds, the estimator-disagreement trap that bites near a cutoff, and why logP sits at the center of the solubility–permeability tradeoff.

What logP measures

logP is the base-10 logarithm of the octanol–water partition coefficient: the ratio of a neutral compound’s concentration in octanol to its concentration in water at equilibrium. Octanol stands in for a lipid membrane, so logP is a proxy for how readily a molecule leaves the aqueous phase and crosses into fat.

How to read a logP value

The sign tells you the direction, the magnitude tells you how far.

• logP < 0 — hydrophilic; the molecule prefers water. Tends toward good solubility, poor membrane permeability.
• logP 1–3 — the rough sweet spot for orally absorbed small molecules. Enough lipophilicity to cross membranes, enough polarity to stay soluble.
• logP > 5 — trips the Lipinski lipophilicity criterion. High first-pass metabolism risk, poor aqueous solubility, and often promiscuous off-target binding.

These are guideposts, not hard lines. CNS candidates often run slightly higher (around logP 2–3) because crossing the blood–brain barrier rewards lipophilicity, while a molecule with great target affinity at logP 4.5 is still worth pursuing — you just know solubility will need attention downstream.

The estimator-disagreement trap

Here is the trap that catches people: logP is computed, not looked up, and different methods compute different numbers. The common estimators — Wildman–Crippen (the method RDKit uses), ClogP, and Crippen–Daylight — can disagree by more than one log unit for the same structure. That spread is larger than the distance between “ideal” and “Ro5 violation,” so an unlabeled logP near a cutoff is close to useless.

The practical habit: never quote a logP in a report, a SAR table, or a slide without the method name. “logP 3.2” invites a silent mismatch the next time someone recomputes it; “logP 3.2 (Wildman–Crippen)” doesn’t. This is the same provenance discipline that applies to canonical versus isomeric SMILES — the representation only means something once you name the convention behind it.

logP and the solubility–permeability tradeoff

logP is the dial at the center of a tradeoff you can’t escape. Push it up and membrane permeability improves but aqueous solubility falls; push it down and solubility improves but the molecule struggles to cross the gut wall. The window where both are workable is narrow, which is why the 1–3 band keeps recurring in oral-drug design.

Lipophilicity also drives metabolism and binding promiscuity: higher logP compounds are cleared faster by oxidative metabolism and bind more off-targets, which is the reasoning behind the “keep logP modest” convention in lead optimization. logP is one input among several — the polar surface area governs a related but distinct part of the absorption story, covered in TPSA permeability thresholds.

Reading logP from the property panel

In ChemStitch, the property panel computes logP by the Wildman–Crippen method through RDKit and labels it as such, alongside MW, HBD, HBA, TPSA, and rotatable bonds. The value is marked Computed (deterministic, green), distinct from any AI Suggested estimate — so you know the logP came from a fixed algorithm, not a generative guess. That label is what makes a logP comparison trustworthy: you can see it’s Wildman–Crippen on both molecules. If you need to confirm a molecular weight before evaluating drug-likeness, the molecular weight calculator computes it directly from a structure or formula. For how logP feeds the drug-likeness badge, see the Lipinski Rule of Five explained.

Read a logP as a method-tagged number on a tradeoff curve, not as an absolute verdict. The estimator is part of the measurement.

References: Lipinski et al., Adv. Drug Deliv. Rev. (DOI: 10.1016/S0169-409X(00)00129-0); RDKit Crippen logP (MolLogP) descriptor documentation (rdkit.org).